Recommendation of Diagnosis and Management for the Infections Related to Immune Checkpoint Inhibitors / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 666-670, 2019.
Artículo
en Chino
| WPRIM
| ID: wpr-775574
ABSTRACT
Immune checkpoint inhibitors (ICIs) have been widely used in management of malignant tumor. Programmed death ligand 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have been introduced to treat non-small cell lung cancer (NSCLC) in recent years. Currently, PD-1/PD-L1 inhibitors are considered to have minor side effects and do not independently increase the risk of infection. However, they may cause immune-related adverse events (irAEs) that can require immunosuppressive therapy with corticosteroids and/or immunosuppressants, leading to opportunistic infections. Furthermore, there were reports about reactivation of chronic/latent infections without irAEs. Thus, immune checkpoint inhibitor related infections have drawn more and more attention in the world. In this paper, we described the potential mechanism, available clinical data and recommendation of diagnosis and management for PD-1/PD-L1 inhibitor related infections.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Estudio diagnóstico
/
Guía de Práctica Clínica
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS